Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 17, 2024, titled "Glenmark Pharmaceuticals receives ANDA approval for Topiramate Capsules USP, 15 mg and 25 mg".
Press Release Jul 17 2024
Filed with NSE · · 2 pages · English
Summary by 6ix AI
The approval allows Glenmark to distribute these capsules in the U.S., which are bioequivalent to Topamax® Capsules. The market for Topamax® Capsules achieved significant annual sales according to recent data. Glenmark's portfolio includes numerous products authorized for distribution in the U.S. and several pending approvals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Press Release Jun 12 2024
- Press Release May 24 2024
- Press Release May 21 2024
- Press Release May 17 2024
- Press Release Apr 29 2024
Later from Glenmark Pharmaceuticals
- Press Release Aug 14 2024
- Glenmark Pharmaceuticals Limited Press Release Aug 19 2024
- Glenmark Pharmaceuticals Limited Press Release Nov 06 2024
- Press Release Nov 14 2024
- Glenmark Pharmaceuticals Limited Press Release Nov 27 2024
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals